An update on the diagnosis and treatment of Parkinson disease
- PMID: 27221269
- PMCID: PMC5088077
- DOI: 10.1503/cmaj.151179
An update on the diagnosis and treatment of Parkinson disease
Conflict of interest statement
Mandar Jog reports honoraria from Merz Pharmaceuticals, Allergan and AbbVie; and grants from the Canadian Institutes of Health Research, Academic Medical Organization of Southwestern Ontario, Lawson Health Research Institute, AGE-WELL Networks of Centres of Excellence, Merz Pharmaceuticals and Boston Scientific. He occasionally serves on advisory boards of Allergan, Boston Scientific, AbbVie and Merz Pharmaceuticals. No other competing interests were declared.
Similar articles
-
Levodopa-carbidopa intestinal gel therapy after deep brain stimulation.Mov Disord. 2018 Feb;33(2):334-335. doi: 10.1002/mds.27211. Epub 2017 Nov 6. Mov Disord. 2018. PMID: 29105810 No abstract available.
-
New and emerging treatments for Parkinson disease.Med J Aust. 2015 Apr 6;202(6):283-4. doi: 10.5694/mja15.00155. Med J Aust. 2015. PMID: 25832138 No abstract available.
-
Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease.Mov Disord. 2011 Mar;26(4):664-70. doi: 10.1002/mds.23524. Epub 2011 Apr 5. Mov Disord. 2011. PMID: 21469197
-
Diagnosis and Treatment of Parkinson Disease: A Review.JAMA. 2020 Feb 11;323(6):548-560. doi: 10.1001/jama.2019.22360. JAMA. 2020. PMID: 32044947 Review.
-
When the going gets tough: how to select patients with Parkinson's disease for advanced therapies.Pract Neurol. 2013 Jun;13(3):140-52. doi: 10.1136/practneurol-2012-000463. Epub 2013 Mar 13. Pract Neurol. 2013. PMID: 23487815 Review.
Cited by
-
Neuroprotection Against Parkinson's Disease Through the Activation of Akt/GSK3β Signaling Pathway by Tovophyllin A.Front Neurosci. 2020 Jul 9;14:723. doi: 10.3389/fnins.2020.00723. eCollection 2020. Front Neurosci. 2020. PMID: 32742256 Free PMC article.
-
The Association Between Parkinson's Disease and Attention-Deficit Hyperactivity Disorder.Cell Transplant. 2020 Jan-Dec;29:963689720947416. doi: 10.1177/0963689720947416. Cell Transplant. 2020. PMID: 33028106 Free PMC article.
-
Lysosomal storage, impaired autophagy and innate immunity in Gaucher and Parkinson's diseases: insights for drug discovery.Philos Trans R Soc Lond B Biol Sci. 2024 Apr 8;379(1899):20220381. doi: 10.1098/rstb.2022.0381. Epub 2024 Feb 19. Philos Trans R Soc Lond B Biol Sci. 2024. PMID: 38368939 Free PMC article. Review.
-
Acanthopanax senticosus Protects Structure and Function of Mesencephalic Mitochondria in A Mouse Model of Parkinson's Disease.Chin J Integr Med. 2018 Nov;24(11):835-843. doi: 10.1007/s11655-018-2935-5. Epub 2018 Aug 8. Chin J Integr Med. 2018. PMID: 30090975
-
Study on the Neuroprotective, Radical-Scavenging and MAO-B Inhibiting Properties of New Benzimidazole Arylhydrazones as Potential Multi-Target Drugs for the Treatment of Parkinson's Disease.Antioxidants (Basel). 2022 Apr 29;11(5):884. doi: 10.3390/antiox11050884. Antioxidants (Basel). 2022. PMID: 35624746 Free PMC article.
References
-
- Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384–6. - PubMed
-
- Twelves D, Perkins KSM, Counsell C. Systematic review of incidence studies of Parkinson’s disease. Mov Disord 2003;18: 19–31. - PubMed
-
- de Lau LML, Breteler MMB. Epidemiology of Parkinson’s disease. Lancet Neurol 2006;5:525–35. - PubMed
-
- de Lau LML, Giesbergen PCLM, de Rijk MC, et al. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology 2004;63:1240–4. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical